July 14, 2024 This Week Top S&P 500 Gainers & Losers
Tesla Q2: The Bottom Is Likely In
Tesla: Time To Take Profits
Microsoft: The Q4 Results Should Surprise You
Tesla: Optimus And FSD Probably Won’t Save The Day
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
Novavax (NVAX) Stock Forecast for 2024–2028. Sell or Buy?
Updated: July 27, 2024 (05:32)
Sector: HealthcareThe share price of Novavax, Inc. (NVAX) now
50/200 Day Moving Average: $14.68 / $7.54
This figure corresponds to the Average Price over the previous 50/200 days. For Novavax stocks, the 50-day moving average is the support level today.
For Novavax stocks, the 200-day moving average is the support level today.
Are you interested in Novavax, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Novavax stock price in 2024, 2025, 2026, 2027, 2028. How much will one Novavax share be worth in 2024 - 2028?
When should I take profit in Novavax stock? When should I record a loss on Novavax stock? What are analysts' forecasts for Novavax stock? What is the future of Novavax stock? We forecast Novavax stock performance using neural networks based on historical data on Novavax stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Novavax stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Novavax shares. This happens once a day.
Historical and forecast chart of Novavax stock
The chart below shows the historical price of Novavax stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Novavax stock price can be found in the table below.
Long-term forecasts by years.
![](https://up2info.com/wp-content/uploads/2024/06/img_6674ea6234a82-scaled.jpg)
NVAX Stock Forecast: Navigating the Impact of the Sanofi Deal and Vaccine Demand
![](/wp-content/uploads/2022/12/neutral.jpg)
As we delve into the future of Novavax (NVAX), two pivotal events stand out that could potentially sway the NVAX stock forecast significantly. First and foremost is the much-discussed partnership with Sanofi, a move that has injected a sense of optimism among investors regarding Novavax's financial stability and market positioning. This arrangement promises a noteworthy flow of royalty revenue by 2025, casting a spotlight on NVAX as a stock to watch. Critically, the ability of Novavax to leverage this deal, despite its limited capabilities in commercialization when pitted against Sanofi's robust operations, poses a complex puzzle for analysts.
Decoding Future Moves: Is NVAX a Good Stock to Buy?
Moreover, the continuously evolving demand for COVID-19 vaccines, including boosters and potential flu/Covid combination vaccines, forms the second fulcrum that will likely influence the NVAX stock price prediction. While the general demand for COVID-19 vaccines has seen a downturn, the booster segment, coupled with ongoing developments, offers a silver lining. Analysts aiming for an accurate NVAX stock forecast would do well to closely monitor these dynamics.
To navigate the turbulent waters of the vaccine market and make informed decisions regarding whether NVAX is a good stock to buy or sell, it is vital to keep a pulse on these influential factors. Knowledge of Novavax's strategies, market demand, and competitive landscape will be critical in predicting the NVAX stock price target. As the situation unfolds, one thing remains clear: NVAX presents both an opportunity and a challenge, making it a stock to watch closely in the coming months.
Review the original Analysis![](https://static3.seekingalpha.com/images/users_profile/000/234/751/medium_pic.png)
![](https://up2info.com/wp-content/uploads/2024/06/img_6670de6fe88c1-scaled.jpg)
Novavax Stock Forecast: Navigating Future Trends with COVID-19 and Bird Flu Developments
![](/wp-content/uploads/2022/12/bullish.jpg)
In the dynamic world of stock market investments, Novavax (NVAX) appears to be at a crucial crossroads with significant factors poised to influence its stock rates in the near future. Analysts keen on making accurate NVAX stock forecasts are closely monitoring two key developments: the progress of the COVID-19 vaccine and the advancement in bird flu vaccine development.
What's Driving Novavax Stocks?
The most immediate impact on NVAX stock prices is expected to come from updates regarding their COVID-19 vaccine. Positive news such as regulatory approvals and expansions in vaccine administration authorization are seen as pivotal. These developments not only enhance confidence in Novavax's revenue-generating capabilities but also validate the efficacy of their vaccine technology. Such milestones could make NVAX a good stock to buy, driving upward momentum in its stock price prediction.
Furthermore, Novavax's strides in bird flu vaccine development using innovative platform technology and high-density nanoparticles hold tremendous potential. Successful clinical trials and potential FDA approval could position NVavax favorably against competitors, adding to the bullish NVAX stock forecast. The ability to quickly develop a vaccine for a growing public health concern could signify a major win for Novavax, potentially increasing the NVAX stock price target.
However, potential investors should not overlook competition risks, especially from giants like Moderna and Pfizer in the COVID-19 space and existing players in the bird flu vaccine market. Analysts attempting to predict whether NVAX stock is a buy or sell must consider how Novavax fares against its competitors. Although competition poses a threat, the unique propositions of Novavax could help it stand out, thus affecting the Novavax name stock forecast.
In conclusion, NVAX stock forecasts hinge on how the company navigates upcoming challenges and leverages opportunities in COVID-19 and bird flu vaccine development. By understanding these factors, analysts can make educated predictions about the future of NVAX stocks, helping investors decide whether to buy or sell Novavax stock.
Review the original Analysis![](https://static2.seekingalpha.com/images/users_profile/048/523/746/medium_pic.png)
![](https://up2info.com/wp-content/uploads/2024/05/img_66410aa52443c-scaled.jpg)
A Renaissance in NVAX Stock: The Sanofi Catalyst and Beyond
![](/wp-content/uploads/2022/12/bullish.jpg)
For investors and analysts tracking Novavax (NVAX), the horizon seems particularly vibrant, pulsing with a mix of challenges and breakthrough opportunities that can sway the NVAX stock price prediction in considerable ways. Central to these developments is the groundbreaking licensing agreement with pharmaceutical titan Sanofi, a strategic partnership poised to inject not only a significant upfront capital boost but also sustained revenue streams through royalties. This collaboration, potentially valued up to $1.2 billion, represents a seismic shift, securing Novavax a coveted spot on the global vaccine stage and fundamentally altering the NVAX stock forecast.
The Pillars of Prediction: Analyzing NVAX's Future Stock Trajectory
To adeptly navigate the Novavax narrative and make informed decisions regarding whether NVAX is a good stock to buy, analysts would do well to dissect the multifaceted aspects influencing its stock rate. Foremost is the Sanofi pact, a veritable game-changer that lends immediate credence and financial bulwark to Novavax. This development alone could serve as a lighthouse, guiding NVAX stock price target adjustments and investor sentiment. Coupled with the recent earnings surpassing EPS expectations, despite a revenue miss, and the strategic forward march in their vaccine pipeline, these elements collectively paint a picture of a company on the verge of a bullish break.
Yet, for a rounded NVAX stock buy or sell analysis, one cannot overlook the inherent challenges—the rigors of market competition, the intricacies of regulatory navigations, and the integration of innovative vaccine technologies into the broader market. These factors, while possibly casting shadows, can also offer the astute analyst a nuanced understanding of the NVAX landscape, enabling a sharper NVAX stock price prediction.
Descending in order of importance, the licensing agreement with Sanofi undoubtedly is the celestial event in the NVAX stock forecast galaxy. Not far behind, the company's financial stability and promising pipeline development cast significant rays of hope for those pondering if NVAX is a good stock to buy. Regulatory trials and market competition, while certainly crucial, somewhat dim in comparison but should not be ignored by any looking to make a buy or sell Novavax stock decision.
In essence, tapping into the most accurate foresight into NVAX's stock trajectory requires a balanced analysis, weighing the monumental partnership with Sanofi against the backdrop of financial, developmental, and market dynamics. These considerations are paramount for those looking to target the NVAX stock price with precision, offering a blueprint for navigating the promising yet unpredictable terrain of Novavax's stock future.
Review the original Analysis![](https://static2.seekingalpha.com/images/users_profile/048/523/746/medium_pic.png)
Novavex, Inc. Together with its subsidiary Novavax AB, a late-stage biotechnology company, it discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company’s leading vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, which is in stage III clinical trials to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in phase III clinical trials for the treatment of seasonal influenza in the elderly. Its leading adjuvant is Matrix-M, which is used to enable the vaccine to enhance the amplitude of the immune response and qualitatively change it, and to allow the immune system to attack microorganisms, and also to allow immunization with much smaller doses of antigen. The company is also developing the RSV F vaccine for the elderly (60 years and older), which is in phase II clinical trials, as well as for healthy children aged six months to five years, who are in phase I clinical trials. In addition, it is developing candidate nanoparticle vaccines for clinical trials against the Ebola virus, which is in clinical trials stage I; and a combined respiratory vaccine to protect against influenza and RSV. In addition, the company is developing a COVID-19 vaccine against the pneumonia-like coronavirus, which is in the preclinical stage. Novavex, Inc. the company was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul 29 | 16.51 | 16.11 | 17.31 | 7.47 |
Jul 30 | 15.90 | 15.20 | 16.49 | 8.47 |
Jul 31 | 16.41 | 15.78 | 16.99 | 7.68 |
Aug 01 | 15.19 | 14.44 | 15.69 | 8.71 |
Aug 02 | 14.74 | 14.22 | 15.39 | 8.21 |
Aug 03 | 15.83 | 15.23 | 16.11 | 5.80 |
Aug 04 | 15.97 | 15.54 | 16.26 | 4.62 |
Aug 05 | 16.60 | 15.84 | 16.93 | 6.89 |
Aug 06 | 17.69 | 16.46 | 18.47 | 12.18 |
Aug 07 | 17.20 | 16.86 | 17.57 | 4.22 |
Aug 08 | 17.69 | 16.77 | 18.47 | 10.16 |
Aug 09 | 17.28 | 16.13 | 18.01 | 11.67 |
Aug 10 | 18.37 | 17.92 | 19.19 | 7.10 |
Aug 11 | 18.27 | 16.97 | 18.81 | 10.85 |
Aug 12 | 18.70 | 17.55 | 19.03 | 8.44 |
Aug 13 | 19.38 | 18.44 | 20.45 | 10.88 |
Aug 14 | 19.56 | 18.73 | 20.84 | 11.28 |
Aug 15 | 19.95 | 19.25 | 21.15 | 9.89 |
Aug 16 | 19.73 | 18.75 | 20.60 | 9.85 |
Aug 17 | 19.34 | 17.97 | 20.09 | 11.82 |
Aug 18 | 19.32 | 18.56 | 20.24 | 9.09 |
Aug 19 | 18.30 | 17.54 | 19.05 | 8.64 |
Aug 20 | 19.14 | 18.26 | 20.33 | 11.32 |
Aug 21 | 20.84 | 20.00 | 21.48 | 7.41 |
Aug 22 | 20.04 | 19.40 | 21.14 | 8.92 |
Aug 23 | 20.41 | 19.59 | 21.85 | 11.54 |
Aug 24 | 19.51 | 18.46 | 20.67 | 11.99 |
Aug 25 | 18.30 | 17.25 | 19.27 | 11.75 |
Aug 26 | 17.30 | 16.95 | 18.11 | 6.79 |
Aug 27 | 17.61 | 17.01 | 18.56 | 9.13 |
Novavax Daily Price Targets
Novavax Stock Forecast 07-29-2024.
Forecast target price for 07-29-2024: $16.51.
Negative dynamics for Novavax shares will prevail with possible volatility of 6.952%.
Pessimistic target level: 16.11
Optimistic target level: 17.31
Novavax Stock Forecast 07-30-2024.
Forecast target price for 07-30-2024: $15.90.
Negative dynamics for Novavax shares will prevail with possible volatility of 7.812%.
Pessimistic target level: 15.20
Optimistic target level: 16.49
Novavax Stock Forecast 07-31-2024.
Forecast target price for 07-31-2024: $16.41.
Positive dynamics for Novavax shares will prevail with possible volatility of 7.130%.
Pessimistic target level: 15.78
Optimistic target level: 16.99
Novavax Stock Forecast 08-01-2024.
Forecast target price for 08-01-2024: $15.19.
Negative dynamics for Novavax shares will prevail with possible volatility of 8.014%.
Pessimistic target level: 14.44
Optimistic target level: 15.69
Novavax Stock Forecast 08-02-2024.
Forecast target price for 08-02-2024: $14.74.
Negative dynamics for Novavax shares will prevail with possible volatility of 7.585%.
Pessimistic target level: 14.22
Optimistic target level: 15.39
Novavax Stock Forecast 08-03-2024.
Forecast target price for 08-03-2024: $15.83.
Positive dynamics for Novavax shares will prevail with possible volatility of 5.482%.
Pessimistic target level: 15.23
Optimistic target level: 16.11
NVAX (NVAX) Monthly Stock Prediction for 2024
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Aug. | 20.02 | 18.82 | 24.82 | 24.19 |
Sep. | 24.76 | 20.46 | 29.59 | 30.88 |
Oct. | 28.03 | 24.00 | 31.48 | 23.78 |
Nov. | 26.35 | 21.21 | 31.17 | 31.95 |
Dec. | 27.14 | 21.85 | 28.77 | 24.06 |
Novavax forecast for this year
Novavax Stock Prediction for Aug 2024
An uptrend is forecast for this month with an optimal target price of $20.02. Pessimistic: $18.82. Optimistic: $24.82
Novavax Stock Prediction for Sep 2024
An uptrend is forecast for this month with an optimal target price of $24.7647. Pessimistic: $20.46. Optimistic: $29.59
Novavax Stock Prediction for Oct 2024
An uptrend is forecast for this month with an optimal target price of $28.0337. Pessimistic: $24.00. Optimistic: $31.48
Novavax Stock Prediction for Nov 2024
An downtrend is forecast for this month with an optimal target price of $26.3517. Pessimistic: $21.21. Optimistic: $31.17
Novavax Stock Prediction for Dec 2024
An uptrend is forecast for this month with an optimal target price of $27.1422. Pessimistic: $21.85. Optimistic: $28.77
Novavax (NVAX) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 33.57 | 26.22 | 37.30 | 29.70 |
Feb | 30.35 | 27.35 | 37.64 | 27.34 |
Mar | 29.53 | 22.71 | 34.14 | 33.48 |
Apr | 27.41 | 24.53 | 29.38 | 16.51 |
May | 27.16 | 23.66 | 29.36 | 19.43 |
Jun | 23.82 | 18.32 | 29.54 | 37.98 |
Jul | 22.46 | 20.51 | 25.36 | 19.13 |
Aug | 28.93 | 26.50 | 32.66 | 18.87 |
Sep | 32.57 | 27.20 | 36.29 | 25.04 |
Oct | 33.75 | 25.65 | 38.51 | 33.39 |
Nov | 33.24 | 26.36 | 35.44 | 25.61 |
Dec | 36.43 | 30.86 | 40.37 | 23.56 |
Novavax (NVAX) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 36.21 | 33.72 | 44.25 | 23.81 |
Feb | 36.11 | 28.41 | 39.14 | 27.40 |
Mar | 30.69 | 25.72 | 37.32 | 31.09 |
Apr | 28.76 | 26.08 | 31.17 | 16.33 |
May | 32.72 | 25.07 | 38.71 | 35.25 |
Jun | 25.36 | 21.71 | 29.77 | 27.09 |
Jul | 31.45 | 25.88 | 33.43 | 22.58 |
Aug | 37.11 | 31.32 | 43.34 | 27.74 |
Sep | 34.21 | 31.24 | 38.22 | 18.26 |
Oct | 41.50 | 31.67 | 48.10 | 34.17 |
Nov | 46.86 | 38.70 | 56.41 | 31.40 |
Dec | 41.09 | 34.93 | 45.90 | 23.90 |
Novavax (NVAX) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 44.30 | 40.44 | 48.55 | 16.70 |
Feb | 32.74 | 29.40 | 40.10 | 26.69 |
Mar | 28.41 | 24.75 | 34.55 | 28.37 |
Apr | 29.95 | 27.61 | 32.11 | 13.99 |
May | 34.17 | 28.02 | 38.07 | 26.39 |
Jun | 33.76 | 28.60 | 41.46 | 31.03 |
Jul | 29.00 | 24.04 | 31.70 | 24.15 |
Aug | 37.44 | 34.97 | 41.15 | 15.01 |
Sep | 37.78 | 29.84 | 44.46 | 32.88 |
Oct | 34.60 | 29.62 | 41.66 | 28.90 |
Nov | 27.96 | 23.68 | 33.66 | 29.65 |
Dec | 28.72 | 22.51 | 32.59 | 30.92 |
Novavax (NVAX) Monthly Stock Prediction for 2028
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 30.35 | 25.71 | 32.81 | 21.65 |
Feb | 31.99 | 29.40 | 38.13 | 22.90 |
Mar | 41.59 | 34.73 | 51.20 | 32.17 |
Apr | 53.69 | 47.89 | 60.13 | 20.36 |
May | 64.32 | 58.73 | 73.20 | 19.77 |
Jun | 62.59 | 52.45 | 71.22 | 26.36 |
Jul | 63.34 | 55.93 | 73.60 | 24.01 |
Aug | 73.22 | 63.77 | 88.15 | 27.66 |
Sep | 78.49 | 68.13 | 94.50 | 27.91 |
Oct | 94.03 | 88.11 | 116.03 | 24.07 |
Nov | 85.00 | 68.43 | 95.46 | 28.32 |
Dec | 82.96 | 66.04 | 92.42 | 28.55 |
Novavax information and performance
20 FIRSTFIELD ROAD, GAITHERSBURG, MD, US
Market capitalization of the Novavax, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of NVAX shares in the company outstanding by the market price of one share.
EBITDA of Novavax is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Novavax (NVAX) stock dividend
Novavax last paid dividends on 01/01/1970. The next scheduled payment will be on 05/10/2019. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.